cells. Am J Clin Pathol . 2007;127:687-700. 21. BenetC,GomezA,AguilarC, et al.Histologicandimmunohistologic characterization of skin localization of myeloid disorders: a study of 173 cases. Am J Clin Pathol . 2011;135:278-290. 22. Petrella T, Meijer CJ, Dalac S, et al. TCL1 and CLA expression in agranular CD4/CD56 hematodermic neoplasms (blastic NK-cell lymphomas) and leukemia cutis. Am J Clin Pathol . 2004;122:307- 313. 23. Vitte F, Fabiani B, Benet C, et al. Specific skin lesions in chronic myelomonocytic leukemia: a spectrum of myelomonocytic and dendritic cell proliferations: a study of 42 cases. Am J Surg Pathol . 2012;36:1302-1316. 24. Jardin F, Callanan M, Penther D, et al. Recurrent genomic aberrations combinedwith deletions of various tumour suppressor genes may deregulate the G1/S transition in CD4+CD56+ haematodermic neoplasms and contribute to the aggressiveness of the disease. Leukemia . 2009;23:698-707. 25. Wiesner T, Obenauf AC, Cota C, Fried I, Speicher MR, Cerroni L. Alterations of the cell-cycle inhibitors p27(KIP1) and p16(INK4a) are frequent in blastic plasmacytoid dendritic cell neoplasms. J Invest Dermatol . 2010;130:1152-1157.
2001:214-215. 2. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood . 2005;105:3768-3785. 3. Jegalian AG, Facchetti F, Jaffe ES. Plasmacytoid dendritic cells: physiologic roles and pathologic states. Adv Anat Pathol . 2009;16:392-404. 4. Facchetti F, Jones DM, Petrella T. Blastic plasmacytoid dendritic cell neoplasm. WHO Classification of tumors of Hematopoietic and Lymphoid Tissues. IARC, Lyon . 2008:145-147. 5. Jaye DL, Geigerman CM, Herling M, Eastburn K, Waller EK, Jones D. Expression of the plasmacytoid dendritic cell marker BDCA-2 supports a spectrum of maturation among CD4+ CD56+ hematodermic neoplasms. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2006;19:1555- 1562. 6. Marafioti T, Paterson JC, Ballabio E, et al. Novel markers of normal and neoplastic human plasmacytoid dendritic cells. Blood . 2008;111:3778-3792. 7. Dalle S, Beylot-Barry M, Bagot M, et al. Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice? Br J Dermatol . 2010;162:74-79. 8. Hashikawa K, Niino D, Yasumoto S, et al. Clinicopathological features and prognostic significance of CXCL12 in blastic plasmacytoid dendritic cell neoplasm. J Am Acad Dermatol . 2012;66:278-291. 9. Lucioni M, Novara F, Fiandrino G, et al. Twenty-one cases of blastic plasmacytoid dendritic cell neoplasm: focus on biallelic locus 9p21.3 deletion. Blood . 2011;118:4591-4594. 10. Jegalian AG, BuxbaumNP, Facchetti F, et al. Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications. Haematologica . 2010;95:1873-1879. 11. Borchiellini D, GhibaudoN, Mounier N, et al. Blastic plasmacytoid dendritic cell neoplasm: a report of four cases and review of the literature. J Eur Acad Dermatol Venereol . 2012. 12. Jardin F, Ruminy P, Parmentier F, et al. TET2 and TP53 mutations are frequently observed in blastic plasmacytoid dendritic cell neoplasm. Br J Haematol . 2011;153:413-416. 13. Zheng G, Schmieg J, Guan H, Ali SZ. Blastic plasmacytoid dendritic cell neoplasm: cytopathologic findings. Acta cytologica . 2012;56:204-208. 14. Facchetti F, Pileri SA, Agostinelli C, et al. Cytoplasmic nucleophosmin is not detected in blastic plasmacytoid dendritic cell neoplasm. Haematologica . 2009;94:285-288. 15. Cota C, Vale E, Viana I, et al. Cutaneous manifestations of blastic plasmacytoid dendritic cell neoplasm-morphologic and phenotypic variability in a series of 33 patients. Am J Surg Pathol . 2010;34:75-87. 16. Petrella T, Bagot M, Willemze R, et al. Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review. Am J Clin Pathol . 2005;123:662-675. 17. Cronin DM, George TI , Rei chard KK, Sundram UN. Immunophenotypic analysis of myeloperoxidase-negative leukemia cutis and blastic plasmacytoid dendritic cell neoplasm. Am J Clin Pathol . 2012;137:367-376. 18. Khoury JD, Medeiros LJ, Manning JT, Sulak LE, Bueso-Ramos C, Jones D. CD56(+) TdT(+) blastic natural killer cell tumor of the skin: a primitive systemic malignancy related to myelomonocytic leukemia. Cancer . 2002;94:2401-2408. 19. Chang HJ, Lee MD, Yi HG, et al. A case of blastic plasmacytoid dendritic cell neoplasm initially mimicking cutaneous lupus erythematosus. Cancer Res Treat . 2010;42:239-243. 20. Herling M, Jones D. CD4+/CD56+ hematodermic tumor: the features of an evolving entity and its relationship to dendritic
Dr. Feng is with the Department of Pathology and Laboratory Medicine at Tulane University School of Medicine in New Orleans. Drs. Zhou and Bentley are with the Department of Pathology at the Detroit Medical Center and Wayne State University School of Medicine.
J La State Med Soc VOL 166 January/February 2014 9
Made with FlippingBook - Online catalogs